Citius Oncology (CTOR) Income from Continuing Operations (2023 - 2026)
Citius Oncology (CTOR) posted quarterly Income from Continuing Operations of 26609695.0 for Q1 2026, down 243.99% year-over-year from 18479956.7 in Q1 2025, and down 380.83% quarter-over-quarter from 5534069.0 in Q4 2025.
Citius Oncology (CTOR) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Citius Oncology (CTOR) has reported Income from Continuing Operations for 4 consecutive years, with 26609695.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 243.99% year-over-year to 26609695.0; the TTM figure through Mar 2026 stood at 42510376.0 (down 11.01% YoY), while the FY2025 annual figure was 24761369.0, down 17.08% from the prior year.
- Income from Continuing Operations fell to 26609695.0 in Q1 2026 per CTOR's latest filing, from 5534069.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 147922.0 in Q1 2023 and bottomed at 26609695.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 7557557.58 across 4 years, with a median of 5452012.5 in 2025.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations sank 7083.92% — and 2025, when it soared 62.54%.
- Citius Oncology's Income from Continuing Operations stood at 4727403.0 in 2023, then plunged by 40.86% to 6659205.0 in 2024, then advanced by 16.9% to 5534069.0 in 2025, then tumbled by 380.83% to 26609695.0 in 2026.
- Business Quant data shows CTOR's Income from Continuing Operations at 26609695.0 in Q1 2026, 5534069.0 in Q4 2025, and 4996656.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Citius Oncology | 83.28 Mn | 83.28 Mn | 1.00 Mn | -8.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.61 Mn |
| Dec 31, 2025 | -5.53 Mn |
| Sep 30, 2025 | -5.00 Mn |
| Jun 30, 2025 | -5.37 Mn |
| Mar 31, 2025 | -7.74 Mn |
| Dec 31, 2024 | -6.66 Mn |
| Jun 30, 2024 | -14.34 Mn |
| Mar 31, 2024 | -9.56 Mn |
| Dec 31, 2023 | -4.73 Mn |
| Sep 30, 2023 | -4.81 Mn |
| Jun 30, 2023 | -199,554.00 |
| Mar 31, 2023 | -147,922.00 |